Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
1.
Clin Oral Investig ; 23(6): 2593-2598, 2019 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-30317400

RESUMO

BACKGROUND: Our aim was to investigate the disease-free survival in patients with tongue squamous cell carcinoma receiving metronomic neoadjuvant chemotherapy with 5-fluorouracil prodrugs (UFT or S-1) plus bleomycin compared with those who had up-front surgery retrospectively. METHODS: In this retrospective study, 108 patients with stages I to II tongue squamous cell carcinoma who had undergone surgery were divided into the "surgery group" or "neoadjuvant chemotherapy group." RESULTS: A total of 41 patients received up-front surgery; 67 received metronomic neoadjuvant chemotherapy with UFT plus bleomycin (39) or S-1 plus bleomycin (28). The rate of disease-free survival was the primary outcome measure. Neoadjuvant 5-fluorouracil prodrugs did not correlate higher with improved disease-free survival than up-front surgery (72 and 54%, respectively; hazard ratio for recurrence or death, 0.54; 95% confidence interval [CI], 0.28 to 1.03; P = 0.06). Patients who received S-1 were more likely than those who received UFT to have pathological complete response (46% vs. 15%; P = 0.007). Neoadjuvant S-1 significantly improved disease-free survival as compared with up-front surgery (79% vs. 54%; hazard ratio, 0.41; 95% CI, 0.15 to 0.98; P = 0.04). However, neoadjuvant UFT did not improve disease-free survival as compared with up-front surgery (67% vs. 54%, respectively; hazard ratio, 0.66; 95% CI, 0.31 to 1.33; P = 0.24). CONCLUSIONS: Neoadjuvant S-1 chemotherapy, as compared with up-front surgery, significantly improved disease-free survival among patients with tongue squamous cell carcinoma. CLINICAL RELEVANCE: A choice of drugs before neoadjuvant metronomic chemotherapy is needed.


Assuntos
Carcinoma de Células Escamosas/tratamento farmacológico , Carcinoma de Células Escamosas/cirurgia , Terapia Neoadjuvante , Neoplasias da Língua/tratamento farmacológico , Neoplasias da Língua/cirurgia , Adulto , Idoso , Idoso de 80 Anos ou mais , Protocolos de Quimioterapia Combinada Antineoplásica , Bleomicina/uso terapêutico , Quimioterapia Adjuvante , Intervalo Livre de Doença , Feminino , Fluoruracila/uso terapêutico , Humanos , Masculino , Pessoa de Meia-Idade , Recidiva Local de Neoplasia , Estadiamento de Neoplasias , Pró-Fármacos/uso terapêutico , Estudos Retrospectivos , Resultado do Tratamento
2.
Mediators Inflamm ; 2011: 263216, 2011.
Artigo em Inglês | MEDLINE | ID: mdl-21822357

RESUMO

To date, the major role of HPV16E6 in cancer has been considered to be its ability to inhibit the p53 tumor-suppressor protein, thereby thwarting p53-mediated cytotoxic responses to cellular stress signals. Here, we show that HPV16E6-dependent c-fos oncogenic protein expression contributes to AP-1 complex formation under oxidative stress in SiHa cells (HPV16-positive squamous cell carcinoma of the cervix). In addition, we examined the role of HPV16E6 in TGF-α-induced c-fos expression and found that the c-fos protein expression induced by TGF-α is HPV16E6 dependent. Thus, our results provide the first evidence that HPV16E6 contributes to AP-1 complex formation after both ligand-dependent and independent EGFR activation, suggesting a new therapeutic approach to the treatment of HPV-associated tumors.


Assuntos
Proteínas Oncogênicas Virais/metabolismo , Proteínas Proto-Oncogênicas c-fos/metabolismo , Proteínas Repressoras/metabolismo , Fator de Transcrição AP-1/metabolismo , Linhagem Celular Tumoral , Feminino , Regulação Neoplásica da Expressão Gênica , Humanos , Proteínas Oncogênicas Virais/genética , Proteínas Proto-Oncogênicas c-fos/genética , RNA Interferente Pequeno/genética , RNA Interferente Pequeno/metabolismo , Proteínas Repressoras/genética , Fator de Transcrição AP-1/genética , Fator de Crescimento Transformador alfa/metabolismo , Neoplasias do Colo do Útero/metabolismo , Neoplasias do Colo do Útero/patologia , Neoplasias do Colo do Útero/virologia
3.
Mediators Inflamm ; 2009: 183760, 2009.
Artigo em Inglês | MEDLINE | ID: mdl-20150959

RESUMO

Inflammation is associated with disease progression and, by largely unknown mechanisms, has been said to drive oncogenesis. At inflamed sites, neutrophils deploy a potent antimicrobial arsenal that includes proteinases, antimicrobial peptides, and ROS. Reactive oxygen species (ROSs) induce chemokines. In the present study, the concentrations of IL-8 in culture supernatants of HeLa cells treated with ROS were determined by enzyme-linked immunosorbent assay. We used o-phenanthroline to deplete Fe(2+) in order to investigate the mechanisms through which ROSs induce IL-8 secretion in our system. The iron chelator o-phenanthroline effectively inhibited H(2)O(2)-induced ERK2 activation. Enzyme-linked immunosorbent assays showed that IL-8 protein secretion was elevated in ROS-treated HeLa cells. When Fe(2+) was removed from these cells, IL-8 secretion was inhibited. Collectively, these results indicate that Fe(2+)-mediated Erk pathway activation is an important signal transduction pathway in ROS-induced IL-8 secretion in epithelial cells.


Assuntos
Quimiocinas/metabolismo , Células Epiteliais/metabolismo , Regulação da Expressão Gênica , Interleucina-8/metabolismo , Ferro/metabolismo , Oxigênio/metabolismo , Anti-Infecciosos/farmacologia , Ensaio de Imunoadsorção Enzimática/métodos , MAP Quinases Reguladas por Sinal Extracelular/metabolismo , Células HeLa , Humanos , Peróxido de Hidrogênio/química , Fenantrolinas/farmacologia , Espécies Reativas de Oxigênio , Transdução de Sinais
4.
Int J Oncol ; 28(5): 1193-9, 2006 May.
Artigo em Inglês | MEDLINE | ID: mdl-16596235

RESUMO

Acyclic retinoid (ACR), a novel synthetic retinoid, has been demonstrated by us to inhibit the in vitro growth of human hepatoma cells, and this effect was associated with modification of cell cycle control molecules, suggesting that this agent may be useful in the chemoprevention and therapy of various types of malignancies. However, whether or not ACR exerts anticancer activities on human colon carcinoma cells has not yet been elucidated. The purpose of this study was to examine the inhibitory effects of ACR in human colon carcinoma cells and to characterize the molecular mechanism of action of this agent. ACR inhibited the growth of the HCT116 and SW480 human colon carcinoma cell lines with IC50 values of about 30 and 60 microM, respectively. ACR also induced G1-phase cell cycle arrest and apoptosis in these cell lines. When the HCT116 cells were treated with 5-25 microM ACR, there was a marked decrease in the cellular levels of cyclin D1 mRNA and an approximate 2.5- to 3-fold increase in those of p21CIP1 mRNA, and this induction occurred via a p53-independent mechanism. Furthermore, ACR induced a dose-dependent mRNA elevation of differentiation markers at concentrations of ACR that affect the levels of expression of p21CIP1. These novel results suggest that ACR inhibits cell proliferation by inducing G1 arrest and apoptosis and that cyclin D1 and p21CIP1 play critical roles in the molecular mechanisms of growth inhibition and differentiation induced by ACR. Collectively, these findings provide further evidence that ACR may be a potential agent for the chemoprevention and therapy of human colon cancer.


Assuntos
Antineoplásicos/farmacologia , Apoptose/efeitos dos fármacos , Regulação Neoplásica da Expressão Gênica/efeitos dos fármacos , RNA Mensageiro/genética , Tretinoína/análogos & derivados , Sequência de Bases , Ciclo Celular/efeitos dos fármacos , Diferenciação Celular/efeitos dos fármacos , Divisão Celular/efeitos dos fármacos , Linhagem Celular Tumoral , Neoplasias do Colo , Primers do DNA , Humanos , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Tretinoína/farmacologia
5.
Eur J Pharmacol ; 553(1-3): 46-53, 2006 Dec 28.
Artigo em Inglês | MEDLINE | ID: mdl-17056031

RESUMO

An anthraquinone derivative, emodin, suppresses tumor development both in vitro and in vivo. In this study, we examined the anti-angiogenic activity of emodin and its modifying effect on the phosphorylation of extracellular signal-regulated kinase (ERK) 1/2. In cell cultures, emodin inhibited endothelial cell proliferation, migration, and tube formation in a dose-dependent manner. In addition, the mouse dorsal air sac assay revealed the vivo anti-angiogenic potential of emodin. Matrix metalloproteinase-9 (MMP-9) expression, which is critical for the angiogenic process, including migration and tube formation, decreased after exposure to emodin, as determined by polymerase chain reaction with reverse transcription (RT-PCR) and gelatin zymography. Moreover, the phosphorylation of ERK 1/2 decreased after exposure to emodin in a dose-dependent manner. These observations suggest that emodin has the potential to inhibit several angiogenic processes and that these effects may be related to suppression of the phosphorylation of ERK 1/2.


Assuntos
Emodina/uso terapêutico , Proteína Quinase 1 Ativada por Mitógeno/metabolismo , Proteína Quinase 3 Ativada por Mitógeno/metabolismo , Neovascularização Patológica/tratamento farmacológico , Animais , Western Blotting , Diferenciação Celular/efeitos dos fármacos , Movimento Celular/efeitos dos fármacos , Proliferação de Células , Células Cultivadas , Quimiotaxia/efeitos dos fármacos , Células Endoteliais/fisiologia , Matriz Extracelular/efeitos dos fármacos , Matriz Extracelular/metabolismo , Humanos , Masculino , Metaloproteinase 9 da Matriz/biossíntese , Metaloproteinase 9 da Matriz/metabolismo , Camundongos , Camundongos Endogâmicos ICR , Microtúbulos/efeitos dos fármacos , Microtúbulos/fisiologia , Fosforilação , RNA Mensageiro/biossíntese , Reação em Cadeia da Polimerase Via Transcriptase Reversa
6.
Anticancer Res ; 26(4B): 2829-32, 2006.
Artigo em Inglês | MEDLINE | ID: mdl-16886601

RESUMO

BACKGROUND: O6-methylguanine-DNA methyltransferase (MGMT) is a DNA repair protein and protects DNA from the biological effects of alkylating carcinogens. The purpose of this study was to investigate the association between the mRNA expression level of the Mgmt gene and mutation of the beta-catenin gene in rat colon tumors induced by azoxymethane (AOM) plus dextran sulfate sodium (DSS). MATERIALS AND METHODS: Eleven tumor samples from rat colon treated by AOM plus DSS were examined. Mutation of the beta-catenin gene was identified by polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) analysis. The expression level of Mgmt mRNA was determined by reverse transcription-PCR (RT-PCR). RESULTS: Four out of five adeno-carcinoma samples bearing beta-catenin gene mutation (5 out of 11, 45%) displayed a decrease in expression levels of Mgmt mRNA (p<0.02). CONCLUSION: These results suggest that the reduced expression of Mgmt mRNA and beta-catenin gene mutation may contribute to the development of rat colon tumors.


Assuntos
Neoplasias do Colo/genética , O(6)-Metilguanina-DNA Metiltransferase/genética , RNA Mensageiro/biossíntese , beta Catenina/genética , Animais , Azoximetano , Neoplasias do Colo/induzido quimicamente , Neoplasias do Colo/enzimologia , Neoplasias do Colo/metabolismo , Sulfato de Dextrana , Masculino , Mutação , O(6)-Metilguanina-DNA Metiltransferase/biossíntese , RNA Mensageiro/genética , Ratos , Ratos Endogâmicos F344
7.
Asian Pac J Cancer Prev ; 7(3): 467-71, 2006.
Artigo em Inglês | MEDLINE | ID: mdl-17059347

RESUMO

The purpose of the present study was to examine whether Neem leaf (Azadirachta indica) has short-term chemopreventive effects on endpoint preneoplastic lesions involved in rat colon carcinogenesis and might also exert antioxidative activity. Forty- two male F344 rats were randomly divided into 6 experimental groups. Groups 1 to 4 were given a subcutaneous injection of azoxymethane (AOM, 20 mg/kg body weight) once a week for 2 weeks. Starting one week before the first injection of AOM, rats in groups 2 to 4 received an aqueous extract of Neem leaf (20, 100, and 250 mg/kg, respectively) by gavage 3 times per week, for 5 weeks. Rats in group 5 also were given the Neem extract by gavage feeding 3 times per week for 5 weeks, while group 6 served as untreated controls. The experiment was terminated 5 weeks after the start. Dietary feeding of the Neem extract at all dose levels significantly inhibited the induction of aberrant crypt foci (ACF) (P<0.0002), when compared to the AOM-treated group (group 1). In groups 2 to 4, treatment of rats with the Neem extract also significantly decreased the proliferating cell nuclear antigen (PCNA) labeling indices (P<0.0006) of colon epithelium and ACF. Moreover, the Neem extract also showed antioxidative activity. The finding that dietary Neem has possible chemopreventive effects in the present short-term colon carcinogenesis bioassay suggests that longer-term exposure may cause suppression of tumor development.


Assuntos
Antioxidantes/farmacologia , Azadirachta/química , Azoximetano/toxicidade , Carcinógenos/toxicidade , Neoplasias do Colo/prevenção & controle , Extratos Vegetais/farmacologia , Lesões Pré-Cancerosas/prevenção & controle , Animais , Antioxidantes/administração & dosagem , Azoximetano/administração & dosagem , Carcinógenos/administração & dosagem , Transformação Celular Neoplásica , Quimioprevenção , Neoplasias do Colo/induzido quimicamente , Neoplasias do Colo/veterinária , Masculino , Fitoterapia/veterinária , Extratos Vegetais/administração & dosagem , Lesões Pré-Cancerosas/induzido quimicamente , Lesões Pré-Cancerosas/veterinária , Ratos , Ratos Endogâmicos F344
8.
Oncol Lett ; 2(1): 21-28, 2011 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-22870123

RESUMO

This study aimed to investigate whether glucose transporter-1 (GLUT-1) expression in a pretreatment esophageal cancer biopsy was predictive of clinical outcomes in patients with esophageal cancer undergoing concurrent chemoradiotherapy (CRT). A total of 25 patients with esophageal cancer treated with concurrent CRT were reviewed. Radiotherapy was administered up to total doses of 40-66.6 Gy (median 66.6 Gy) with a single fraction of 1.8-2 Gy. Regarding chemotherapy, cisplatin (80 mg/m(2) on day 1) and 5-fluorouracil (800 mg/m(2) on days 2-6) were used concurrently with radiotherapy, every 3-4 weeks for a total of 1-2 courses. Tissue samples from esophageal carcinoma were obtained from the 25 patients by biopsy prior to concurrent CRT, and a semiquantitative analysis of GLUT-1 expression was performed using immunohistochemical staining. High GLUT-1 expression was observed in 7 of 25 (28%) patients, and GLUT-1 expression was significantly correlated with clinical T stage (p=0.0454), clinical N stage (p=0.0324) and initial response to CRT (p=0.0185). Patients with a high GLUT-1 expression had significantly poorer local control (LC) (5-year LC 28.6%) than those with a low expression (5-year LC 73.4%, p<005). Multivariate analysis revealed that GLUT-1 and the number of chemotherapy courses were independent prognostic factors for LC. Patients with a high GLUT-1 expression had significantly lower recurrence-free survival (RFS) compared to those with a low GLUT-1 expression (p=0.0405). Multivariate analysis revealed that GLUT-1, the number of chemotherapy courses and clinical M stage were independent prognostic factors for RFS. GLUT-1 expression was significantly correlated with clinical T stage, clinical N stage and initial response to concurrent CRT, and was predictive of LC and RFS for patients with esophageal cancer treated with concurrent CRT.

9.
Oncol Rep ; 23(2): 337-44, 2010 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-20043093

RESUMO

Transgenic rats carrying human c-Ha-ras proto-oncogene (Hras128 rats) have been shown to be highly susceptible to induction of tumors. We have found an early induction of tongue tumors in Hras128 rats treated with 4-nitroquinoline 1-oxide (4NQO). 4NQO was administered to the Hras128 and wild-type Sprague-Dawley (SD) rats for 4 and 8 weeks, respectively. The experiment was terminated at 14 (Hras128 rats) and 28 (SD rats) weeks. Either during or after treatment with 4NQO, dysplastic hyperplasia, papilloma and squamous cell carcinoma were found on the tongue of both Hras128 and wild-type rats, with a higher incidence and multiplicity in Hras128 rats. Treatment of the Hras128 rats with 4NQO significantly increased cell proliferation in the tumor compared to the control rats. In the tongue tumors of the Hras128 rats, there was a significant increase in the mRNA expression levels of cyclin D1 and COX2. To examine whether this experimental system is useful for screening of the candidate agents for cancer preventive effect, nimesulide, a selective COX2 inhibitor, was tested in the present model. Nimesulide significantly decreased total multiplicity of tongue lesions compared to the control rats. Treatment of Hras128 rats with nimesulide caused a significant decrease in the levels of mRNA expression of cyclin D1 and COX2 in the tumor. Therefore, the current 4NQO-induced Hras128 rat tongue carcinogenesis model provides a simple and rapid system for investigating carcinogenesis process and evaluating the effect of possible cancer preventive agents for human tongue cancer.


Assuntos
4-Nitroquinolina-1-Óxido/efeitos adversos , Carcinoma de Células Escamosas/induzido quimicamente , Carcinoma de Células Escamosas/genética , Transformação Celular Neoplásica/efeitos dos fármacos , Transformação Celular Neoplásica/genética , Proteínas Proto-Oncogênicas p21(ras)/genética , Neoplasias da Língua/induzido quimicamente , Neoplasias da Língua/genética , 4-Nitroquinolina-1-Óxido/farmacologia , Animais , Carcinoma de Células Escamosas/epidemiologia , Carcinoma de Células Escamosas/mortalidade , Sinergismo Farmacológico , Predisposição Genética para Doença , Humanos , Incidência , Masculino , Papiloma/induzido quimicamente , Papiloma/epidemiologia , Papiloma/genética , Papiloma/mortalidade , Proto-Oncogene Mas , Ratos , Ratos Sprague-Dawley , Ratos Transgênicos , Neoplasias da Língua/epidemiologia , Neoplasias da Língua/mortalidade
10.
Mol Med Rep ; 2(1): 45-9, 2009.
Artigo em Inglês | MEDLINE | ID: mdl-21475789

RESUMO

The aim of the present study was to examine whether crude glycosphingolipid (cGSL) has short-term chemopreventive effects on the preneoplastic biomarker lesions involved in carcinogen-induced rat colon carcinogenesis. We also examined whether cGSL affects cell proliferation and apoptosis in these lesions. The crude preparation was obtained by the simple ethanol extraction method. Five-week-old male F344 rats were divided into 6 groups. Rats in groups 1-4 were given subcutaneous injections of azoxymethane (AOM) (20 mg/kg body weight) once a week for 2 weeks. Starting 1 week before the first injection of AOM, the rats in groups 2, 3 and 4 were fed a diet containing 250, 1,000 and 3,000 ppm cGSL, respectively, for 5 weeks. The experiment was terminated 5 weeks after the start date, and the number of aberrant crypt foci (ACF) and mucin-depleted foci (MDF) was counted. Dietary cGSL significantly inhibited the induction of ACF (group 3, P<0.01; group 4, P<0.05) and MDF (groups 2 and 3, P<0.001; group 4, P<0.05) as compared to group 1 treated with AOM alone. In groups 3 and 4, proliferating cell nuclear antigen-positive indices of epithelial cells were significantly lower than in group 1 (group 3, P<0.05; group 4, P<0.005). Caspase-3-positive indices were significantly higher in groups 3 and 4 than in group 1 (group 3, P<0.01; group 4, P<0.001). These results suggest that dietary cGSL had a potent chemopreventive effect in the present short-term colon carcinogenesis bioassays, and that this effect may be associated with the inhibition of ACF and MDF and the induction of apoptosis.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA